表紙
市場調查報告書

呼吸道融合病毒(RSV)的流行病學的預測

Respiratory Syncytial Virus: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 912102
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
呼吸道融合病毒(RSV)的流行病學的預測 Respiratory Syncytial Virus: Epidemiology Forecast to 2028
出版日期: 2019年07月31日內容資訊: 英文 46 Pages
簡介

本報告提供全球主要7個國家 (美國、德國、法國、義大利、西班牙、英國、日本) 的呼吸道融合瘤病毒 (呼吸道融合病毒(RSV),RSV)的發病情形與今後預測相關分析,疾病的特徵,及目前患病者的發病情形,今後10年的患病數量的預測值等調查評估

第1章 目錄

第2章 呼吸道融合病毒(RSV):摘要整理

第3章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
  • 過去的世界趨勢
  • 預測手法
    • 利用的/沒利用的資訊來源
    • 預測的前提條件與手法
  • RSV住院患者數的流行病學的預測 (今後11年份)
    • 成人的RSV住院患者數 (RSV陽性檢驗)
    • 兒童的RSV住院患者數
  • RSV疫苗接種的利用人數的預測 (今後11年份)
    • 早產的數量:各妊娠期間
    • 慢性肺部疾病 (CLD) 發病的早產兒的人數
    • 血液動力學方面患有嚴重心臟疾病的新生兒的人數
    • DMD (裘馨氏肌肉萎縮症)的已受診患病人數
    • SMA (脊髓性肌萎縮症)的已受診患病人數
    • 妊娠後期 (第3期)的孕婦的人數
    • 靠看護設施/長期療養設施生活的成人患者的人數
  • 討論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER210-19

Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death.

It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less than one year old and one of the leading causes of respiratory disease in older adults. Currently RSV has neither a known cure nor a vaccine; however, preventive measures can be taken to help mitigate the spread of the disease

GlobalData epidemiologists provide a well-rounded, evidence-based analysis and forecast for the hospitalized and prophylactic populations for RSV in this report. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Each population, including the hospitalized population, is also segmented by ages and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized markets in the 7MM.

Scope

  • The Respiratory Syncytial Virus (RSV) Epidemiology Report and Model provide an overview of the risk factors and global trends RSV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiology forecast It also includes a 10-year epidemiology forecast for the pediatric and adult populations hospitalized due to RSV infection (hospitalized population) in the 7MM, in addition to the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population). The prophylactic population consists of: children born before 37 weeks of gestation (preterm population); preterm births with neonatal chronic lung disease (CLD); live births with hemodynamically significant congenital heart disease; boys, 0-2 years old, with Duchenne muscular dystrophy (DMD); children, 0-2 years old, with spinal muscular atrophy (SMA); pregnant women in the third trimester; adults ages 55 years or older living in nursing homes (long-term-care institutions).
  • The RSV epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The RSV Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global RSV market.
  • Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RSV therapeutics in each of the markets covered.
  • Understand magnitude of RSV population by both therapeutic and prophylactic markets.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Respiratory Syncytial Virus: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources Used and Not Used
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for RSV Hospitalized Population (2018-2028)
    • 3.5.1 Number of Hospitalized Adults with Positive RSV Test
    • 3.5.2 Number of Children Hospitalized for RSV
  • 3.6 Epidemiological Forecast for RSV Prophylactic Population (2018-2028)
    • 3.6.1 Number of Preterm Births by Gestational Age
    • 3.6.2 Preterm Infants with CLD
    • 3.6.3 Number of Live Births with Hemodynamically Significant Heart Disease
    • 3.6.4 Diagnosed Prevalent Cases of DMD
    • 3.6.5 Number of Diagnosed Prevalent Cases of SMA
    • 3.6.6 Number of Third Trimester Pregnant Women
    • 3.6.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions
  • 3.7 Discussion
    • 3.7.1 Epidemiological Forecast Insight
    • 3.7.2 Limitations of Analysis
    • 3.7.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: 7MM, Summary of the Prophylactic Population in 2018
  • Table 2: Risk Factors for Severe RSV

List of Figures

  • Figure 1: 7MM, Children, Boys and Girls, 0-2 Years Old, Confirmed RSV Hospitalizations, N, 2008-2018
  • Figure 2: 7MM, Rate of Preterm Births (per 1,000 Live Births), 2008-2018
  • Figure 3: 7MM, Percentage of Adults Living in Long-Term Care, Age